RMD
RESMED INC
NYSE · Healthcare · Medical - Instruments & Supplies · US
$237.75
+4.70%Year over year
Reported trailing growth
- Revenue
- +9.0%
- EBITDA
- +12.3%
- EBIT
- +8.9%
- EPS
- +12.0%
- Free cash flow
- +61.2%
- Operating cash flow
- +65.8%
Forward estimates
Based on analyst estimates
- Revenue
- +2.6%
- EBITDA
- +5.5%
- EPS
- +12.0%
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- +16.5%
- EBIT
- +19.0%
- Net income
- +19.3%
- EPS
- +19.5%
- Free cash flow
- +43.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026